Journal article · 2022 · Open access

The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life

Ke Zhou, Martine Marie Bellanger, Sophie Le Lann, Marie Robert, Jean‐Sébastien Frenel, Mario Campone

Frontiers in Oncology, 12, 925534 · Published 14 October 2022 · DOI 10.3389/fonc.2022.925534

Open full textCite this paper

In brief

“The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life” is a 2022 journal article by Ke Zhou and 5 co-authors, published in Frontiers in Oncology. OpenAlex counts 14 citations as of 22 November 2026, which puts it in the top 8% of works published in 2022 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Oncology.

Citations
14
Most cited in
2024 (5)
Field-weighted impact
1.10
References
43
Authors
6

Abstract

Purpose: Patient-reported outcomes (PROs) have been widely used to measure breast cancer (BC) treatment outcomes. However, evidence is still limited on using routinely PROs to personalize treatment decision-making, including or not chemotherapy, targeted therapy, and radiotherapy. Using patient baseline PRO scores, we aimed to use PROs before treatment initiation to predict improvement or decline in health-related quality of life (HRQoL) due to treatment that they receive. Methods: In two French cancer sites, women with non-metastatic BC completed the EORTC QLQ-C30 and QLQ-BR23 and BREAST-Q questionnaires to assess their PROs at baseline and again at 6 months. The outcome measured was post-operative change in PROs with minimal important difference for QLQ-C30 domains. We performed multivariate ordinal logistic regression to estimate the incremental probability of post-operative PRO improvements and deteriorations depending upon treatment options and baseline HRQoL. Results: One hundred twenty-seven women completed questionnaires. Chemotherapy had significant negative impacts on Global health status (GHS) and on physical and social functioning. Chemotherapy and radiotherapy increased patient fatigue scores after adjusting for clinical factors (p< 0.01 and p< 0.05, respectively). The incremental probability of GHS deteriorations for chemotherapy was +0.3, +0.5, and +0.34 for patients with baseline GHS scores of 40, 70, and 100, respectively. This showed that different pre-treatment PROs might predict differential effects of chemotherapy on women change in HRQoL. Conclusion: Patients with different baseline PRO scores may experience dissimilar impacts from BC treatments on post-operative PROs in terms of improvements and deteriorations. Oncologists might decide to adapt the treatment option based on a given level of the negative impact. Future studies should concentrate on incorporating this information into routine clinical decision-making strategies to optimize the treatment benefit for patients.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Zhou, K., Bellanger, M. M., Le Lann, S., Robert, M., Frenel, J., & Campone, M. (2022). The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life. Frontiers in Oncology, 12, 925534. https://doi.org/10.3389/fonc.2022.925534

MLA 9

Zhou, Ke, et al. “The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life.” Frontiers in Oncology, vol. 12, 2022, p. 925534. https://doi.org/10.3389/fonc.2022.925534.

Chicago

Zhou, Ke, Martine Marie Bellanger, Sophie Le Lann, Marie Robert, Jean‐Sébastien Frenel, and Mario Campone. 2022. “The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life.” Frontiers in Oncology 12: 925534. https://doi.org/10.3389/fonc.2022.925534.

Harvard

Zhou, K. et al. (2022) ‘The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life’, Frontiers in Oncology, 12, p. 925534. doi:10.3389/fonc.2022.925534.

IEEE

K. Zhou, M. M. Bellanger, S. Le Lann, M. Robert, J. Frenel, and M. Campone, “The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life,” Frontiers in Oncology, vol. 12, p. 925534, 2022, doi: 10.3389/fonc.2022.925534.

BibTeX

@article{zhou2022predictive,
  title     = {{The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life}},
  author    = {Zhou, Ke and Bellanger, Martine Marie and Le Lann, Sophie and Robert, Marie and Frenel, Jean‐Sébastien and Campone, Mario},
  journal   = {Frontiers in Oncology},
  year      = {2022},
  volume    = {12},
  pages     = {925534},
  doi       = {10.3389/fonc.2022.925534},
  url       = {https://doi.org/10.3389/fonc.2022.925534}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202322
202455
202544
202633

Its field-weighted citation impact is 1.10: it has been cited 1.10 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › Cancer survivorship and care

  • breast cancer
  • patient-reported outcomes
  • health-related quality of life
  • chemotherapy
  • radiotherapy
  • treatment-related quality of life
  • baseline quality of life
  • treatment decision-making

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Zhou, K., Bellanger, M. M., Le Lann, S., Robert, M., Frenel, J., & Campone, M. (2022). The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life. Frontiers in Oncology, 12, 925534. https://doi.org/10.3389/fonc.2022.925534

How many times has this paper been cited?

14 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Oncology: sign in and open the full text from this page.

Who wrote this paper?

Ke Zhou, Martine Marie Bellanger, Sophie Le Lann, Marie Robert, Jean‐Sébastien Frenel, Mario Campone.

What is the DOI of this paper?

10.3389/fonc.2022.925534, permanently at https://doi.org/10.3389/fonc.2022.925534. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.